Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

This is an interventional treatment trial for Metastatic Pancreatic Cancer Read More

Inclusion Criteria:

• Patients with histologic or cytologic diagnosis of stage IV metastatic pancreatic adenocarcinoma.
• One or more tumors measurable on CT scan.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
• Life expectancy of at least 3 months.
• Age ≥ 18 years.
• Signed, written IRB-approved informed consent.
• A negative pregnancy test (if female and of child-bearing potential).

• Acceptable liver function:

  • Bilirubin ≤ 1.5 times upper limit of normal
  • AST (SGOT), ALT (SGPT) ≤ 3.0 x ULN
  • Serum creatinine ≤ 1.5 X ULN

• Acceptable hematologic status:

  • Absolute neutrophil count ≥ 1500 cells/mm³
  • Platelet count ≥ 100,000 (plt/mm³)
  • Hemoglobin ≥ 10 g/dL

• Acceptable blood sugar control

  *Fasting glucose value ≤ 160 mg/dL

• Urinalysis: No clinically significant abnormalities.
• PT and PTT ≤ 1.5 X ULN
• For men and women of child-producing potential, willingness to use of effective contraceptive methods during the study.
• NOT have received any prior cytotoxic chemotherapy or investigational therapy. However, this study may be used as 2nd line treatment of patients who progressed on or were intolerant of 1st line FOLFIRINOX for the primary or metastatic disease. Prior treatment with gemcitabine administered as radiation sensitizer in the adjuvant setting is allowed, provided at least 6 months have elapsed since completion of the last dose and no lingering toxicities are present.
• They also must NOT have received chemotherapy, radiotherapy, surgery or investigational therapy for the treatment of metastatic disease.
• Organ function characterized by ≤ Grade 1.

Exclusion Criteria:

• Patient has received any prior cytotoxic chemotherapy for pancreatic cancer with the exception of patients who progressed on or were intolerant of 1st line FOLFIRINOX in primary or metastatic disease. Prior treatment with gemcitabine administered as a radiation sensitizer in the adjuvant setting is allowed, provided at least 6 months have elapsed since completion of the last dose and no lingering toxicities are present. Patients who previously had and were treated with standard therapy for non-pancreatic cancer will be evaluated for entry into the trial on a case-by-case basis.
• New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, unstable angina (chest pain greater than three times weekly while on therapy), evidence of ischemia on ECG, or abnormal stress echocardiogram with evidence of ischemia, or LVEF < 50%.
• Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
• Treated with antibiotics for infection within one week prior to study entry.
• Fever (> 38.1°C)
• Have hematological malignancy
• Have diastolic blood pressure of > 90 mm Hg resting at baseline despite medication.
• Pregnant or nursing women.
• Treatment with surgery, or investigational therapy within 28 days prior to study entry or radiation therapy within 6 months prior to study entry.
• Have received chemotherapy, radiotherapy, surgery or investigational therapy for the treatment of metastatic disease.
• Unwillingness or inability to comply with procedures required in this protocol.
• Known infection with HIV, Hepatitis B, or Hepatitis C.
• Serious nonmalignant disease that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
• Patients who are currently receiving any other investigational agent.
• Patients who are currently taking Coumadin or Coumadin derivatives other than to maintain patency of venous access lines.
• Receiving systemic steroids or other chronic immunosuppressive medications within 30 days prior to study entry
• Receiving hematopoietic growth factors on a regular basis

• Had within six months prior to enrollment any of the following:

  • Cerebrovascular accident
  • Uncontrolled congestive heart failure
• Have significant baseline neuropathies
• Requires renal dialysis
• Had prior exposure to gene vector delivery products
• Had previously experienced a severe hypersensitivity reaction to gemcitabine or nab-paclitaxel